Search results for "ATRIAL-FIBRILLATION"

showing 10 items of 12 documents

Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism-Results from the thrombEVAL Study.

2020

Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011&ndash

medicine.medical_specialtyANTITHROMBOTIC THERAPYPULMONARY-EMBOLISMvenous thromboembolismlcsh:Medicine030204 cardiovascular system & hematologyRate ratioWARFARINArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineORAL ANTICOAGULATION030212 general & internal medicineAdverse effectcoagulation serviceINR CONTROLNORMALIZED RATIO CONTROLPRACTICAL MANAGEMENTbusiness.industrySTROKE PREVENTIONlcsh:RHazard ratioWarfarinAtrial fibrillationGeneral Medicinemedicine.diseaseConfidence intervalMEDICAL-CAREPulmonary embolismvitamin K antagonistsATRIAL-FIBRILLATIONe-healthbusinessoral anticoagulation therapymedicine.drugJournal of clinical medicine
researchProduct

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease

2021

Platelets are the main players in thrombotic diseases, where activated platelets not only mediate thrombus formation but also are involved in multiple interactions with vascular cells, inflammatory components, and the coagulation system. Although in vitro reactivity of platelets provides information on the function of circulating platelets, it is not a full reflection of the in vivo activation state, which may be relevant for thrombotic risk assessment in various disease conditions. Therefore, studying release markers of activated platelets in plasma is of interest. While this type of study has been done for decades, there are several new discoveries that highlight the need for a critical a…

0301 basic medicineACUTE MYOCARDIAL-INFARCTIONVON-WILLEBRAND-FACTORDEEP VENOUS THROMBOSISvenous thromboembolismCD40 LIGANDContext (language use)ReviewDiseaseCardiovascular Medicinearterial thrombosis030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineVon Willebrand factorPERIPHERAL ARTERY-DISEASENONVALVULAR ATRIAL-FIBRILLATIONmedicineDiseases of the circulatory (Cardiovascular) systematrial fibrillationPlateletACUTE ISCHEMIC-STROKEMyocardial infarctionPlatelet activationThrombusthrombosisbiologybusiness.industryACUTE CORONARY SYNDROMESbiomarkersmedicine.diseaseThrombosisC-REACTIVE PROTEIN3. Good healthP-SELECTIN LEVELS030104 developmental biologyRC666-701plateletsbiology.proteinCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Economic evaluation of prolonged and enhanced ECG Holter monitoring in acute ischemic stroke patients

2019

Objective: Atrial fibrillation (AF) is a major cause for recurrent stroke, has severe impact on a patient's health and imposes a high economic burden for society. Current guidelines recommend 24 h ECG monitoring (standard-of-care, SoC) to detect AF after stroke to reduce the risk of future events. However, paroxysmal AF (PAF) is difficult to detect within this period as it occurs infrequently and unpredictably. In a randomized controlled trial (Find-AF(RANDOMISED)), prolonged and enhanced Holter ECG monitoring (EPM) revealed a significantly higher detection rate of AF compared to SoC, although its cost-effectiveness has not yet been investigated. Methods: Based on the data of FIND-AF(RANDOM…

AdultMalemedicine.medical_specialtymacromolecular substancesCOST-EFFECTIVENESS ANALYSIS030204 cardiovascular system & hematologyGUIDELINESTHERAPYBrain Ischemia03 medical and health sciences0302 clinical medicineRecurrent strokeInternal medicinemedicineMANAGEMENTHumanscardiovascular diseases030212 general & internal medicinequality-adjusted life yearsAcute ischemic strokeStrokeAgedAged 80 and overbusiness.industrycost-benefit analysisAtrial fibrillationGeneral MedicineCost-effectiveness analysisMiddle AgedWirtschaftswissenschaftenmedicine.diseaseAtrial fibrillationstroke3. Good healthQuality-adjusted life yearTRIALSEconomic evaluationATRIAL-FIBRILLATIONCardiologyElectrocardiography AmbulatoryQuality of LifeFemalebusinessHolter monitoringsecondary preventionTASK-FORCE
researchProduct

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

2018

AbstractAtherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1. Risk factors, biomarkers and plaque inst…

0301 basic medicinemedicine.medical_specialtyanticoagulantsADJUST ANTIPLATELET THERAPYPERCUTANEOUS CORONARY INTERVENTION030204 cardiovascular system & hematologyarterial thrombosisArticleantiplatelet therapyACTIVATED PROTEIN-CRED-BLOOD-CELLS03 medical and health sciences0302 clinical medicineVITAMIN-K ANTAGONISTSInternal medicineatherothrombosisIschaemic strokeNONVALVULAR ATRIAL-FIBRILLATIONmedicinePlateletatrial fibrillationACUTE ISCHEMIC-STROKEcoagulationATOMIC-FORCE MICROSCOPYCardiovascular mortalityischaemic strokeAtomic force microscopybusiness.industryConsensus conferenceHematologymedicine.diseaseThrombosis030104 developmental biologymyocardial infarctionCoagulationplateletsDIRECT ORAL ANTICOAGULANTSCardiologyPosition paperSYMPTOMATIC VENOUS THROMBOEMBOLISMatherosclerosisbusiness
researchProduct

Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

2018

AbstractPatients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outc…

MaleAdministration Oralheart failureclinical outcomeED AMERICAN-COLLEGE030204 cardiovascular system & hematologyTHERAPY ANTITHROMBOTIC THERAPYCohort StudiesPhenprocoumon0302 clinical medicinequality of careGermanyProspective Studies030212 general & internal medicineProspective cohort studyAged 80 and overOUTCOMESIncidenceHazard ratioHematologyTreatment OutcomeCohortFemaleCLINICAL-PRACTICE GUIDELINESSINUS RHYTHMmedicine.drugCohort studyRiskmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHemorrhageWARFARINEJECTION FRACTION03 medical and health sciencesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryWarfarinhealth care modelAnticoagulantsmedicine.diseaseoral anti-coagulationHeart failureATRIAL-FIBRILLATIONPhenprocoumonADVERSE EVENTSbusinessANTICOAGULANT-THERAPY
researchProduct

Thrombin generation in cardiovascular disease and mortality – results from the Gutenberg Health Study

2020

Thrombin generation may be a potential tool to improve risk stratification for cardiovascular diseases. The aim of this study was to explore the relation between thrombin generation and cardiovascular risk factors, cardiovascular diseases, and total mortality. For this study, 5,000 subjects from the population-based Gutenberg Health Study were analyzed in a highly standardized setting. Thrombin generation was assessed by the Calibrated Automated Thrombogram method at 1 and 5 pM tissue factor triggers in platelet-poor plasma. Lag time, endogenous thrombin potential, and peak height were derived from the thrombin generation curve. Sex-specific multivariable linear regression analysis adjusted…

medicine.medical_specialtyPercentilePopulationDiseaseDETERMINANTS030204 cardiovascular system & hematologyFACTOR PATHWAY INHIBITORVALIDATIONArticle03 medical and health sciencesTissue factor0302 clinical medicineInternal medicineMedicineeducationPlatelet-poor plasmaeducation.field_of_studyCOAGULATION-FACTORSPLASMAbusiness.industryProportional hazards modelCALIBRATED AUTOMATED THROMBOGRAMHazard ratioORAL-CONTRACEPTIVESHematologymedicine.diseaseObesityTISSUE FACTOROBESITYATRIAL-FIBRILLATIONCardiologybusiness030215 immunologyHaematologica
researchProduct

e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study

2017

Essentials e-Health based health care by an expert centre may advance management of oral anticoagulation. Outcome of patients was compared between an e-health based coagulation service and regular care. Patients in the coagulation service cohort experienced a significantly better clinical outcome. Lower risk for adverse events was related to anticoagulation-specific and non-specific outcome. SummaryBackground Management of oral anticoagulation (OAC) therapy is essential to minimize adverse events in patients receiving vitamin K-antagonists (VKAs). Data on the effect of e-health-based anticoagulation management systems on the clinical outcome of OAC patients are limited. Objectives To compar…

MalePediatricsVitamin KAdministration OralComorbidity030204 cardiovascular system & hematologyRate ratioSERVICE0302 clinical medicineRisk FactorsGermanyUSUAL MEDICAL-CAREClinical endpointProspective Studies030212 general & internal medicineAged 80 and overOUTCOMESHazard ratioDABIGATRANHematologyMiddle AgedHospitalizationTreatment OutcomeCohortdelivery of healthcareFemaleepidemiologyPatient SafetytelemedicineCohort studymedicine.drugmedicine.medical_specialtyanticoagulantsHemorrhageLower riskpatient outcome assessmentWARFARIN03 medical and health sciencesThromboembolismmedicineNONVALVULAR ATRIAL-FIBRILLATIONHumansQUALITYInternational Normalized RatioAdverse effectBlood CoagulationMETAANALYSISAgedProportional Hazards ModelsRivaroxabanbusiness.industrySTROKE PREVENTIONRIVAROXABANbusinessFollow-Up Studies
researchProduct

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. < 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

0301 basic medicineMalevitamin K antagonistEXTERNAL VALIDATIONTime FactorsVitamin KWarfarin/therapeutic use030204 cardiovascular system & hematologyTHERAPYSeverity of Illness Indexlaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawRecurrenceAtrial FibrillationVitamin K/antagonists & inhibitorsStrokeRISKAtrial fibrillationHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedrisk assessment modelTIMEPREDICTSTreatment OutcomeAnticoagulants/therapeutic useResearch DesignANTICOAGULATION CONTROLFemaleLife Sciences & Biomedicinemedicine.drugHemorrhage/drug therapyAdultmedicine.medical_specialtyRandomizationmedicine.drug_classvenous thromboembolismHemorrhageRisk AssessmentSensitivity and SpecificityEDOXABAN03 medical and health sciencesDouble-Blind MethodVITAMIN-K ANTAGONISTSInternal medicinemedicineNONVALVULAR ATRIAL-FIBRILLATIONORAL ANTICOAGULANTHumansInternational Normalized RatioBlood CoagulationScience & Technologybusiness.industryquality of treatmentWarfarinAnticoagulantsmedicine.diseasewarfarinClinical trial030104 developmental biologyPeripheral Vascular DiseasechemistryBlood Coagulation/drug effectsAtrial Fibrillation/bloodCardiovascular System & CardiologyLinear ModelsWarfarinbusinessVenous Thromboembolism/drug therapyThrombosis and haemostasis
researchProduct

Low-Cost Optical Mapping Systems for Panoramic Imaging of Complex Arrhythmias and Drug-Action in Translational Heart Models.

2017

[EN] Panoramic optical mapping is the primary method for imaging electrophysiological activity from the entire outer surface of Langendorff-perfused hearts. To date, it is the only method of simultaneously measuring multiple key electrophysiological parameters, such as transmembrane voltage and intracellular free calcium, at high spatial and temporal resolution. Despite the impact it has already had on the fields of cardiac arrhythmias and whole-heart computational modeling, present-day system designs precludes its adoption by the broader cardiovascular research community because of their high costs. Taking advantage of recent technological advances, we developed and validated low-cost opti…

0301 basic medicineCARDIAC ELECTROPHYSIOLOGYComputer scienceSwineINGENIERIA MECANICAElectrophysiological Phenomena030204 cardiovascular system & hematology0302 clinical medicineTachycardiaIntracellular free calciumComputer visionMultidisciplinaryCardiac electrophysiologyRabbit heartOptical ImagingHeartCor MalaltiesDiagnòstic per la imatgeCosts and Cost AnalysisVENTRICULAR-FIBRILLATIONTACHYCARDIACardiovascular researchPersistent Atril-FibrillationFisiologiaModels BiologicalArticleMECHANISMSTECNOLOGIA ELECTRONICA03 medical and health sciencesOptical imagingSpatio-Temporal AnalysisOptical mappingPERSISTENT ATRIAL-FIBRILLATIONAnimalsBioenginyeriaVOLTAGESistema cardiovascularModality (human–computer interaction)3-DIMENSIONAL SURFACE RECONSTRUCTIONEPICARDIAL ACTIVATIONbusiness.industryArrhythmias CardiacElectrophysiological PhenomenaElectrophysiology030104 developmental biology3-Dimensional Surface ReconstructionTemporal resolutionRABBIT HEARTArtificial intelligencebusinessACTION-POTENTIALS
researchProduct

Epidemiology of stroke in Europe and trends for the 21st century

2016

International audience; Despite major improvements in primary prevention and acute treatment over the last decades, stroke is still a devastating disease. At the beginning of the 21st century, the age-standardized incidence of stroke in Europe ranged from 95 to 290/100,000 per year, with one-month case-fatality rates ranging from 13 to 35%. Approximately 1.1 million inhabitants of Europe suffered a stroke each year, and ischemic stroke accounted for approximately 80% of cases. Although global stroke incidence is declining, rates observed in young adults are on the rise, thus suggesting a need for strategies to improve prevention. In addition, because of the ageing population, the absolute n…

MalePopulation ageingPediatricsmedicine.medical_specialtyLacunar strokeDijonDisease030204 cardiovascular system & hematologyLacunar stroke03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemAcute careEpidemiologymedicineHumans30-day case-fatalityRecurrent strokeTransient ischemic attackStrokeAtrial-fibrillationDepression (differential diagnoses)business.industryIncidenceIncidence (epidemiology)General Medicine[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosismedicine.disease3. Good healthEuropeStrokeRisk-factorsCognitive impairmentPopulation registryFemalebusiness030217 neurology & neurosurgeryDemography
researchProduct